Kaitlin M. Kestenberg-Messina - Jul 30, 2025 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role: COO and SVP, Compliance
Signature: /s/ Kaitlin M. Kestenberg-Messina, by Michael A. Goldstein as Attorney-in-fact
Stock symbol: ADMA
Transactions as of: Jul 30, 2025
Transactions value $: -$7
Form type: 4
Date filed: 8/1/2025, 09:00 PM
Previous filing: Jul 28, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kestenberg-Messina Kaitlin M.	COO and SVP, Compliance	C/O ADMA BIOLOGICS, INC., 5800 PARK OF COMMERCE BLVD. NW, BOCA RATON	/s/ Kaitlin M. Kestenberg-Messina, by Michael A. Goldstein as Attorney-in-fact	2025-08-01	0002017423

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADMA	Common Stock	Options Exercise	$22.5K	+2.5K	+0.51%	$8.98	490K	Jul 30, 2025	Direct
transaction	ADMA	Common Stock	Tax liability	-$22.5K	-1.21K	-0.25%	$18.59	489K	Jul 30, 2025	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADMA	Employee Stock Option (right to buy)	Options Exercise	$0	-2.5K	-100%	$0.00	0	Jul 30, 2025	Common Stock	2.5K	$8.98	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements and payment by the Reporting Person of the option exercise price. This is not an open market sale of securities. This option was automatically exercised on the expiration date.
F2	Includes, as of the transaction date (i) 77,784 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 144,240 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 15,000 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date;
F3	(continued from footnote 2) (iv) 47,500 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (v) 10,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vi) 194,166 shares of common stock directly owned by the reporting person, which includes the option exercise described in footnote 1 and prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
F4	The option was granted on July 30, 2015 and is fully vested.